By Alicia Gailliez, Business Development Manager, One Nucleus
Antibody drug conjugates (ADCs) show huge potential as a mode of targeted cancer treatment, as revealed recently in cancer trials. Take, for example, AstraZeneca and Daiichi Sankyo’s Enhertu, which significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in the Phase II DESTINY-Gastric01 trial. Enhertu cut the risk of death by 41% compared with chemotherapy. An analysis published in the New England Journal of Medicine showed that patients treated with T-DM1 had a 50% lower risk of…
By Jasmin Bannister, Business Development Manager, One Nucleus
Advanced therapy describes medicines for human use that are based on genes, tissues or cells. In this blog, I will be focusing on the evolution of cell therapy and gene therapy focused trends in deal flow. Whist cell therapy and gene therapy both aim to treat, prevent or cure diseases, they are quite different in their approach. Cell therapy focuses on treating diseases by manipulating cells and can involve restoring the function of damaged cells or using modified cells to deliver a therapeutic effect. Gene therapy aims to treat…